SALT LAKE CITY, May 23, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a worldwide leader in personalized medicine, today announced seven new commercial coverage decisions for Prolaris ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback